Dr Raymond Martin Harris, MD | |
500 5th Street, Brookings, OR 97415 | |
(541) 412-2000 | |
(541) 412-2081 |
Full Name | Dr Raymond Martin Harris |
---|---|
Gender | Male |
Speciality | Pediatrics |
Location | 500 5th Street, Brookings, Oregon |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1174591879 | NPI | - | NPPES |
1083656367 | Other | OR | CURRY MEDICAL CENTER NPI |
1487696985 | Other | OR | CURRY GENERAL HOSPITAL NPI |
500674435 | Medicaid | OR |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208000000X | Pediatrics | MD167743 (Oregon) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Raymond Martin Harris, MD 500 5th St, Brookings, OR 97415-9702 Ph: (541) 412-2000 | Dr Raymond Martin Harris, MD 500 5th Street, Brookings, OR 97415 Ph: (541) 412-2000 |
News Archive
Bayer HealthCare Pharmaceuticals announced today that the U.S. Food and Drug Administration has approved a new storage option for Kogenate FS, antihemophilic factor, now allowing the product to be stored at room temperature for up to one year.
AMAG Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for the approval of ferumoxytol, an intravenous (IV) iron therapy, for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease.
A study of clinical errors made by resident physicians in a teaching hospital reveals that the more tired they are the more mistakes they make. The study published in the International Journal of Behavioural and Healthcare Research puts figures to this seemingly obvious conclusion and shows that fewer errors are made if clinical practices are standardised.
Epilepsy Therapy Project, a non-profit organization whose mission is to accelerate new therapies for people living with epilepsy and seizures, and ICVrx, LLC, a pharmacy product research and development company focused on novel therapies for central nervous system disorders, announced today that ETP has made an investment in ICVrx to support the development of ICVrx's targeted epilepsy drug technology for patients whose seizures are not controlled by current therapies.
› Verified 7 days ago